Risk Determinations For Companion Diagnostics In Oncology Streamlined By US FDA
Information about an investigational drug and companion in vitro diagnostics may be submitted in a single investigational new drug application to the agency's drug or biologics centers, eliminating the need for a separate submission to the device center – unless the diagnostic is determined to be a serious risk, FDA says in draft guidance.
You may also be interested in...
The promise of next-generation sequencing technology to help patients understand risk and target treatment for disease is high. US FDA is hoping to help accelerate practical advancements with the release of two final guidances addressing NGS technology and databases that aggregate genomic information.
In many cases, investigational in vitro diagnostic devices used for targeted therapeutic product studies must undergo their own independent US FDA review, separate from the drug being studied, the agency warns in a draft guidance document on investigational IVDs.
Three months after the official launch of the Oncology Center for Excellence, applications for cancer products are now being reviewed by OCE medical teams. OCE Director Richard Pazdur provides more details on the process and procedures of the newly established center in a podcast interview.